

Application No.	:	10/672,477	Confirmation No.	8232
Applicant	:	Rhonda A. Mills		
Filed	:	September 26, 2003		
TC/A.U.	:	1645		
Docket	:	121,013		
Customer No.	:	23397		
For	:	Method for Simultaneous Evaluation of a Sample Containing a		
		Cellular Target and a Soluble Analyte		

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure provisions of 37 CFR 1.56, Applicant hereby submits Form PTO/SB/08B and a copy of the references that should be considered by the Examiner in connection with the substantive examination process.

No item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application.

In the event that fees should accompany this paper, the Commissioner is hereby authorized to charge the appropriate fee to Deposit Account 03-3410.

Respectfully submitted,

Mitchell S. Allen

Mitchell E. Alter
Attorney for Applicant
Registration No. 28,684
(305)380-3636

Address correspondence to:
Customer Number 23397


CERTIFICATE OF MAILING

I HEREBY CERTIFY that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date set forth below.

NAME Maria Rodriguez

SIGNED Harold Under

DATE October 19, 2004 8 Y



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/672,477
		Filing Date	September 26, 2003
		First Named Inventor	Rhonda A. Mills
		Art Unit	1645
		Examiner Name	
Sheet 1	of 3	Attorney Docket Number	121,013

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALBERIO, L., et al., "Rapid Determination of Anti-Heparin/Platelet Factor 4 Antibody Titers in the Diagnosis of Heparin-Induced Thrombocytopenia", Am J Med, 114:528-536 (2003)	
		AMIRAL, J., et al., "Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effectson platelet activation", Br J Haematol, 109:336-341 (2000)	
		BIRHIRAY, R.E., et al., Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H", Leukemia, 16:861-864 (2002)	
		CHILVER-STAINER, L., et al., "Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems", Thromb Haemost, 91:276-282 (2004)	
		CHONG, B.H., et al., "Heparin-induced thrombocytopenia", J Thromb Haemost, 1:1471-1478 (2003)	
		CLARKE, L.E., "Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy", J Cutan Pathol, 30:459-462 (2003)	
		DAVIS, T.A., et al., "Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression", Clin Cancer Res, 5:611-615 (1999)	
		DEBOIS, W.J., et al., "Diagnosis and treatment of heparin-induced thrombocytopenia", Perfusion, 18:47-53 (2003)	
		DUMONT, F.J., "CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond", Expert Rev Anticancer Ther, 2:23-35 (2002)	
		GILES, F.J., et al., "Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease", Br J Haematol, 123:850-857 (2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/672,477
		Filing Date	September 26, 2003
		First Named Inventor	Rhonda A. Mills
		Art Unit	1645
		Examiner Name	
Sheet 2	of 3	Attorney Docket Number	121,013

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GINALDI, L, et al., "Levels of Expression of CD52 in Normal and Leukemic B and T Cells: Correlation with In vivo Therapeutic Responses to Campath-1H", Leuk Res, 22:185-191 (1997)	
		GOBBI, G., et al., "New Laboratory Test in Flow Cytometry for the Combined Analysis of Serologic and Cellular Parameters in the Diagnosis of Heparin-Induced Thrombocytopenia", Cytometry, 58B:32-38 (2004)	
		KENNEDY, G.A., et al., "Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review", Br J Haematol, 119:412-416 (2002)	
		LINDHOFF-LAST, E., et al., "Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia", Br J Haematol, 113:886-890 (2001)	
		MASON, D.Y., et al., "Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen", Am J Pathol, 136:1215-1222 (1990)	
		REBELLO, P., et al., "Anti-globulin Responses to Rat and Humanized Campath-1 Monoclonal Antibody Used to Treat Transplant Rejection", Transplantation, 68:1417-1420 (1999)	
		REBELLO, P., et al., "Pharmacokinetics of CAMPATH-1H: assay development and validation", J Immunol Methods, 260:285-302 (2002)	
		REILLY, R.F., "The Pathophysiology of Immune-mediated Heparin-induced thrombocytopenia", Seminars in Dialysis, 16:54-60 (2003)	
		TAYLOR, V.C., et al., "Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism", Biochem J, 322(Pt 3):919-925 (1997)	
		TAZZARI, P.L., "Heparin-induced thrombocytopenia: detection of antiheparin/PF4 antibodies by means of heparin/PF4-coated beads and flow cytometry", Transfus Med, 12: 193-198 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/672,477
		Filing Date	September 26, 2003
		First Named Inventor	Rhonda A. Mills
		Art Unit	1645
Examiner Name			
Attorney Docket Number	121,013		
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		UNTCH, B., et al., "Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia, The pathogenic role of IgG", Thromb Res, 105:117-123 (2002)	
		VITALE, M., et al., "Comparison Between Different Laboratory Tests for the Detection and Prevention of Heparin-Induced Thrombocytopenia", Cytometry, 46:290-295 (2001)	
		VUN, C.M., et al., "Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin", Br J Haematol, 112:69-75 (2001)	
		International Council for Standardization in Haematology Expert Panel on Cytometry and Int'l. Soc. of Lab. Hematol. Task Force on Platelet Counting, "Platelet Counting by the RBC/Platelet Ratio Method, A Reference Method", Am J Clin Pathol, 115:460-464 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.